Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 2, 2026, 3:37 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 745–768 of 1,428 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: opiates Clear all
Completed Phase 1Phase 2 Interventional Results available

Drug-drug Interaction Study of Lemborexant as an Adjunctive Treatment for Buprenorphine/Naloxone for Opioid Use Disorder

NCT04818086
View directory record Official record
Conditions
Drug Interaction, Analgesics, Opioid Use Disorder
Interventions
Lemborexant, Placebo, Buprenorphine-naloxone
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 13, 2024 · Synced Nov 2, 2026, 3:37 PM EST
Terminated Phase 4 Interventional

Novel Induction to Buprenorphine/Naloxone

NCT05644587
View directory record Official record
Conditions
Opioid Use Disorder, Opioid Use, Opioid Abuse, Opioid Misuse, Opioid Dependence
Interventions
buprenorphine/naloxone
Drug
Lead sponsor
Bicycle Health
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 20, 2024 · Synced Nov 2, 2026, 3:37 PM EST
Completed Phase 2 Interventional Results available

Reduction of Opioid Dose Using Conditioning & Open-Label Placebo (COLP) in Intensive Rehabilitation

NCT03906721
View directory record Official record
Conditions
Spinal Cord Injuries, Polytrauma, Burn Injury, Pain Management
Interventions
Placebo, Oxycodone, Essential Oil
Drug · Other
Lead sponsor
Spaulding Rehabilitation Hospital
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Charlestown, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Nov 2, 2026, 3:37 PM EST
Recruiting No phase listed Observational Accepts healthy volunteers

Opioid Use Disorder in Pregnancy in Long-Term Maternal/Infant Outcomes

NCT03923374
View directory record Official record
Conditions
Opioid-use Disorder, Opioid Use, Unspecified, Buprenorphine Dependence
Interventions
Subutex / Buprenorphine, Fetal & Neonatal MRI, DNA/Genetic/Pharmacokenetic Blood Draws
Drug · Diagnostic Test
Lead sponsor
Senthil Sadhasivam
Other
Eligibility
18 Years and older · Female only
Enrollment
600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2026
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Nov 2, 2026, 3:37 PM EST
Completed Phase 4 Interventional Results available

The Combination of Adductor Canal Block and Periarticular Injection. A Novel Technique for Patients Undergoing Total Knee Replacement (ACB PAI)

NCT02292082
View directory record Official record
Conditions
Osteoarthritis
Interventions
Bupivacaine, Morphine, Methylprednisolone, Cefazolin, Normal saline, Midazolam, Propofol, Dexamethasone, 8 MHz. Chiba needle, 22 G / 4 inches
Drug · Device
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
18 Years to 80 Years
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 11, 2019 · Synced Nov 2, 2026, 3:37 PM EST
Recruiting Phase 3 Interventional

Emergency Department-Initiated Medications for Alcohol Use Disorder

NCT05827159
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
Naltrexone Pill, Naltrexone Injection, Brief Negotiation Interview, Gabapentin Pill
Drug · Behavioral
Lead sponsor
Yale University
Other
Eligibility
18 Years to 80 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Nov 2, 2026, 3:37 PM EST
Completed Phase 1Phase 2 Interventional Results available

Buprenorphine Pharmacometric Open Label Research Study of Drug Exposure

NCT03608696
View directory record Official record
Conditions
Neonatal Abstinence Syndrome, Neonatal Opiate Withdrawal Syndrome
Interventions
Buprenorphine
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
Up to 4 Weeks
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 11, 2022 · Synced Nov 2, 2026, 3:37 PM EST
Not yet recruiting Not applicable Interventional

Battlefield Acupressure for Acute Back Pain Management in the Emergency Department

NCT07771686
View directory record Official record
Conditions
Acute Back Pain
Interventions
Battlefield auricular acupressure, Sham
Procedure
Lead sponsor
Hackensack Meridian Health
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Nov 2, 2026, 3:37 PM EST
Completed Phase 3 Interventional Accepts healthy volunteers

Combination Gerotherapeutic Interventions for Healthspan Improvement

NCT07475546
View directory record Official record
Conditions
Healthspan Improvement, Aging, Longevity
Interventions
Rapamycin, Naltrexone, Metformin, NAD+, GSH, Infinite Supplement, Placebo/control, B12, Intervention: Guided Meditation Program, Control: Podcast Listening Activity, Control: Standard Exercise Regimen, Intervention: Structured Exercise Program
Drug · Dietary Supplement · Behavioral
Lead sponsor
AgelessRx
Industry
Eligibility
60 Years to 80 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 30, 2026 · Synced Nov 2, 2026, 3:37 PM EST
Not listed Phase 4 Interventional

Nasal Naloxone for Narcotic Overdose

NCT01912573
View directory record Official record
Conditions
Drug Overdose
Interventions
Intranasal (IN) naloxone, Intravenous (IV) naloxone, Intramuscular (IM) naloxone, Intraosseus (IO) naloxone
Drug
Lead sponsor
Judith Feinberg
Other
Eligibility
12 Years and older
Enrollment
236 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
3
States / cities
Batavia, Ohio • Portsmouth, Ohio • West Union, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 31, 2013 · Synced Nov 2, 2026, 3:37 PM EST
Terminated Phase 3 Interventional

Naloxone Hydrochloride Study for Relief of Pruritus in Patients With MF or SS Forms of CTCL

NCT02811783
View directory record Official record
Conditions
Mycosis Fungoides, Lymphoma, T-Cell, Cutaneous, Sézary Syndrome
Interventions
Naloxone Hydrochloride Lotion, 0.5%, Placebo Lotion
Drug
Lead sponsor
Elorac, Inc.
Industry
Eligibility
21 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
16
States / cities
Little Rock, Arkansas • Duarte, California • Palo Alto, California + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2022 · Synced Nov 2, 2026, 3:37 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics of Oxycodone and PF614 Co-Administered with Nafamostat (PF614-MPAR-101)

NCT05090280
View directory record Official record
Conditions
Pharmacokinetics
Interventions
PF614 solution, Naltrexone Hydrochloride, Nafamostat Mesylate
Drug
Lead sponsor
Ensysce Biosciences
Industry
Eligibility
18 Years to 55 Years
Enrollment
111 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Sep 24, 2024 · Synced Nov 2, 2026, 3:37 PM EST
Completed Phase 3 Interventional Results available

Safety Study of Oxycodone Hydrochloride and Naltrexone Hydrochloride Extended-Release Capsules in Subjects With Moderate to Severe Chronic Noncancer Pain

NCT01428583
View directory record Official record
Conditions
Chronic Noncancer Pain
Interventions
oxycodone HCl and naltrexone HCl extended-release capsules
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
395 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
32
States / cities
DeLand, Florida • Jacksonville, Florida • Jupiter, Florida + 27 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2016 · Synced Nov 2, 2026, 3:37 PM EST
Not listed Phase 2 Interventional Accepts healthy volunteers

Bandage Contact Lenses for Corneal Abrasions

NCT03206723
View directory record Official record
Conditions
Corneal Abrasion, Eye Trauma
Interventions
Bandage contact lens, Eyedrop, Hydrocodone
Device · Drug
Lead sponsor
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated Feb 1, 2018 · Synced Nov 2, 2026, 3:37 PM EST
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Intermittent Oral Naltrexone Enhanced With an Ecological Momentary Intervention for Methamphetamine-using MSM

NCT04791969
View directory record Official record
Conditions
Methamphetamine Use Disorder
Interventions
Naltrexone Hydrochloride, Placebo, Ecological Momentary Intervention
Drug · Behavioral
Lead sponsor
Glenn-Milo Santos
Other
Eligibility
18 Years to 70 Years · Male only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 27, 2025 · Synced Nov 2, 2026, 3:37 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of Naloxegol on Gastric, Small Bowel, and Colonic Transit in Healthy Subjects

NCT02737059
View directory record Official record
Conditions
Constipation Drug Induced
Interventions
Naloxegol, Codeine, codeine placebo, naloxegol placebo
Drug
Lead sponsor
Michael Camilleri
Other
Eligibility
18 Years to 65 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 30, 2017 · Synced Nov 2, 2026, 3:37 PM EST
Completed Not applicable Interventional Results available

Contingency Management to Enhance Office-Based Buprenorphine Treatment

NCT04024059
View directory record Official record
Conditions
Opioid-use Disorder
Interventions
Contingency Management for adherence, Contingency Management for abstinence
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 100 Years
Enrollment
375 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 12, 2025 · Synced Nov 2, 2026, 3:37 PM EST
Completed No phase listed Observational

PG and PK of Oxycodone to Personalize Post-op Pain Management Following Surgery in Children

NCT03495388
View directory record Official record
Conditions
Postoperative Pain, Opioid Dependence
Interventions
Oxycodone
Drug
Lead sponsor
Senthil Sadhasivam
Other
Eligibility
8 Years to 18 Years
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
2
States / cities
Indianapolis, Indiana • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 11, 2025 · Synced Nov 2, 2026, 3:37 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Study in Healthy Volunteers to Investigate the Effects of Quinidine on the Pharmacokinetics of NKTR-118

NCT01533155
View directory record Official record
Conditions
Drug Induced Constipation
Interventions
Nektar 118, Quinidine, Quinidine placebo, Morphine
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
214 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 15, 2014 · Synced Nov 2, 2026, 3:37 PM EST
Completed Phase 2 Interventional

Activity Monitoring Assessment of Opiate Withdrawal - 4

NCT00000335
View directory record Official record
Conditions
Opioid-Related Disorders
Interventions
Morphine
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
21 Years to 55 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 1996
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jan 31, 2017 · Synced Nov 2, 2026, 3:37 PM EST
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Control of Cognition (Naltrexone, Methylphenidate, and ADHD Study (NMAS))

NCT01993108
View directory record Official record
Conditions
Healthy, Attention Deficit Hyperactivity Disorder
Interventions
Methylphenidate, Naltrexone, Placebo
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 35 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 18, 2018 · Synced Nov 2, 2026, 3:37 PM EST
Completed Phase 2 Interventional Results available

Study of CA-008 (Vocacapsaicin) in Bunionectomy Patients

NCT03599089
View directory record Official record
Conditions
Post-surgical Pain
Interventions
CA-008, Placebo, Ketorolac, Acetaminophen, Oxycodone, Bupivacaine Hydrochloride
Drug
Lead sponsor
Concentric Analgesics
Industry
Eligibility
18 Years to 75 Years
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
3
States / cities
Pasadena, California • Pasadena, Maryland • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 11, 2021 · Synced Nov 2, 2026, 3:37 PM EST
Completed Not applicable Interventional Results available

Parent/Nurse Controlled Analgesia in the Neonatal Intensive Care Unit

NCT01823497
View directory record Official record
Conditions
Abdominal Surgery, Thoracic Surgery
Interventions
Morphine
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
1 Minute to 70 Days
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 2, 2020 · Synced Nov 2, 2026, 3:37 PM EST